Bluebird bio Inc is a pioneering biotech firm focused on developing innovative gene therapies for severe genetic disorders. Its notable products include ZYNTEGLO for ß-thalassemia, a blood disorder; treatments for sickle cell disease; and SKYSONA for cerebral adrenoleukodystrophy, a rare brain condition. With a strong commitment to addressing unmet medical needs, Bluebird bio combines cutting-edge science with a deep understanding of genetic diseases to offer new hopes for patients. Founded in 1992 and based in Somerville, Massachusetts, the company continues to lead in the gene therapy space.